December 20, 2012
The Food and Drug Administration (FDA) is requiring a black box warning on the Vertex Pharmaceuticals hepatitis C medication Incivek due to a potentially fatal skin rash. The FDA says that patients taking Incivek in combination with the medications ribavirin and interferon, which is taken by injection, should stop taking it immediately if they develop a rash that becomes worse or develops in tandem with other symptoms, such as fever, diarrhea, or mouth sores. The black box warning is the most serious form of safety warning available for medications.
12.19.2012; Associated Press
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|'Caring at Its Essence': HIV Nurses Recall Pivotal Moments With Patients|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|In Their Words: Burdens of HIV Nursing Include Lack of Respect and Resources|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|